
UK MHRA Grants Innovation Passport to ILiAD Biotech’s BPZE1 Intranasal Pertussis Vaccine
ILiAD Biotechnologies, a clinical-stage biotech company focused on preventing and treating diseases caused by Bordetella pertussis and other respiratory pathogens, announced that the U.K. Medicines & Healthcare Products Regulatory Agency (MHRA) has granted its BPZE1 next-generation intranasal pertussis vaccine the…












